Kitov Pharmaceuticals Holdings Ltd., of Tel Aviv, Israel, priced its U.S. offering of about 3.2 million American depository shares (ADS) and warrants to purchase up to about 3.2 million additional ADSs at a combined price of $4.13 for expected gross proceeds of about $13 million.